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Background and Objectives: Electronic pneumatic in-
jection (EPI) is a technique for dermal drug delivery, which
is increasingly being used in clinical practice. However, only
few studies have been reported on cutaneous drug dis-
tribution and related clinical endpoints. We aimed to visu-
alize the immediate cutaneous drug distribution, changes
in skin architecture, and related clinical endpoint of EPI.
Study Design/Materials and Methods: Acridine or-
ange (AO) solution was administered to ex vivo porcine
skin by EPI at pressure levels from 4 to 6 bar with a fixed
injection volume of 50 µl and nozzle size of 200 µm. Im-
mediate cutaneous distribution was visualized using ex
vivo confocal microscopy (EVCM). Changes in skin ar-
chitecture were visualized using both EVCM and hema-
toxylin and eosin‐stained cryosections.
Results: The defined immediate endpoint was a clinically
visible papule formation on the skin. The pressure
threshold to consistently induce a papule was 4 bar, ach-
ieving delivery of AO to the deep dermis (2319 µm axial and
5944 µm lateral distribution). Increasing the pressure level
to 6 bar did not lead to significant differences in axial and
lateral dispersion (P= 0.842, P= 0.905; respectively). A
distinctively hemispherical distribution pattern was iden-
tified. Disruption of skin architecture occurred in-
dependently of pressure level, and consisted of sub-
epidermal clefts, dermal vacuoles, and fragmented collagen.
Conclusions: This is the first study to relate a reprodu-
cible clinical endpoint to EPI‐assisted immediate drug
delivery using EVCM. An EPI‐induced skin papule in-
dicates dermal drug delivery throughout all layers of the
dermis, independent of pressure level settings. Lasers
Surg. Med. © 2020 The Authors. Lasers in Surgery and
Medicine published by Wiley Periodicals LLC
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INTRODUCTION
The skin functions as an effective barrier against
external influences. When intending to deliver drugs
intradermally, conventional syringe‐needle injection is the
standard of care technique to overcome this barrier.
Despite their low cost, wide availability, and ease of use,
needle injections have several disadvantages including
pain, needle‐phobia (24% of adults [1]), and the risk of
needle stick injuries. To overcome these restraints, other
physical delivery techniques have been developed to
provide effective intradermal drug delivery [2]. These
techniques include laser‐assisted drug delivery, micro-
needling, electrochemotherapy, iontophoresis, and jet
injectors [3–7].
Jet injectors are needle‐free injection devices that can
deliver liquids into the skin using a high‐pressure stream.
The recently introduced next‐generation jet injectors are
electronic pneumatic injection systems, which dispense
fluids into the skin via accelerated, compressed gas. This
minimally invasive and needle‐free technique reduced
occupational hazards, while providing drug delivery into
the dermis leaving only a small entry point in the epi-
dermis and a visible papule on the skin [8]. While the
electronic pneumatic injection (EPI) device is more
expensive and larger than spring‐loaded jet injectors,
clinical advantages of EPI include adjustable settings
(pressure level and volume), ease of use in an outpatient
clinic, minimal patient discomfort, and disposable nozzles
and syringes to prevent contamination [9].
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Optical imaging can be a valuable tool when the clinical
utility of the various device parameters is explored. To
investigate EPI parameters, skin‐imitating media such as
polyacrylamide gel and gelatin phantom have been used
previously [10–12]. Moreover, EPI of ink followed by skin
splitting and macroscopic evaluation, and histology
imaging with hematoxylin and eosin (H&E) staining have
also been used for optical imaging of EPI [10,11,13–15].
Although transparent media provide a clear view of in-
jected fluid patterns, skin phantoms are currently lacking
the technical refinement to mimic the biological com-
plexity of human skin [16]. Macroscopic evaluation of skin
tissue does display drug distribution but lacks detailed
illustration of skin compartments and tissue alterations.
Finally, cryosections can be used to inspect the cutaneous
microstructure. The proneness to artifacts and inherent
need for a multistep staining procedure to achieve suffi-
cient image contrast, however, supports the use of novel
optical imaging techniques to supplement traditional
histology when assessing novel drug delivery techniques
[17]. Fluorescence confocal microscopy can overcome these
limitations by visualizing immediate EPI‐induced fluo-
rescent drug distribution without destructive tissue
preparation or additional staining steps.
The ex vivo confocal microscopy (EVCM) uses a laser
system to obtain high‐resolution images of excised tissue
[18]. The device used in the present study uses two lasers
to generate both fluorescence (FCM) and reflectance con-
focal microscopy (RCM) images [19]. AO is most com-
monly used as contrast agent due to its high fluorescent
yield, rapid staining and its well‐established use in re-
search [20]. EVCM is also being investigated to assess the
margin control of basal cell carcinoma during micro-
graphic Moh's surgery to shorten procedure time without
sacrificing accuracy [21–28].
Visualization of immediate EPI‐induced drug dis-
tribution at a microscopic level may provide a better un-
derstanding of its mechanism of action and clinical utility.
Therefore, we aimed to visualize the immediate cutaneous
drug distribution and changes in skin architecture using
EVCM, and focus on the related clinical endpoint of EPI.
MATERIALS AND METHODS
Study Design
In this experimental ex vivo porcine study, immediate
EPI‐induced drug distribution was investigated with
EVCM (n= 22 samples) and changes in skin architecture
were investigated using EVCM and frozen histology
(n= 33 samples). This study was conducted at the De-
partment of Dermatology at the Bispebjerg Hospital in
Copenhagen, Denmark.
Intervention
Flank skin samples from three Danish mixed‐race Land-
race/Yorkshire/Duroc pigs (3 months, 31–44kg) stored at
−80℃ were thawed at room temperature for 30minutes.
Hair was trimmed using an electric razor. Skin samples were
placed on plastic film surrounded by moist gauze for the
duration of the experiment. AO (MW: 301.8Da, excitation
wavelength= 500nm, emission wavelength= 526nm)
(Mavig, Munich, Germany) was used as a contrast agent for
EVCM [29]. The stock solution of 10mg/ml was diluted in
phosphate‐buffered saline to a concentration of 0.06mg/ml.
Saline was used for control injections. EPI was performed
with a needle‐free electronic pneumatic injection device
(EnerJet2.0; PerfAction Technologies Ltd., Rehovot, Israel)
(Fig. 1C). The device has a fixed nozzle size of 200 µm. A
volume of 50 µl was delivered per injection (device range;
50–150 µl) with pressure levels of 4 and 6bar corresponding
50% and 100% pressures of the device (device range; 2–6bar).
Immediately after EPI, a caliper measured the diameter of
the papular skin reaction by LB. Clinical photos were cap-
tured with a DSLR camera (EOS 750D; Canon) under
standardized conditions.
Biopsy Processing and Evaluation of EVCM Images
Biopsy samples were bisected at the point of injection,
placed on a glass slide, and flattened using a second slide
and adhesive putty. The samples were mounted on an
EVCM (Vivascope 2500; Mavig) to capture images of RCM
(488 nm) and FCM (785 nm), respectively, at 50% and 15%
intensity. EVCM provided automatic integration of RCM
and FCM into pseudo‐colored composite images. Reso-
lution of the images was 1024 × 1024 pixels.
Axial and lateral dispersion of AO in dermis were
manually assessed by a nonblinded evaluator (LB) on
FCM images. Axial distribution was defined as the per-
pendicular distance between the basal layer down to the
deepest observed AO signal. Lateral distribution was de-
fined as the maximum lateral expanse of AO signal, par-
allel to the epidermis.
Qualitative assessment of FCM, RCM, and composite
images was performed by inspecting skin compartments,
point of EPI entry, AO distribution pattern, and skin ar-
chitecture disruption.
Evaluation of Frozen Histology
Samples for histological analyses were collected after
EPI to assess changes in skin architecture. Cry-
osectioning, using a cryostat and freezing medium
(Tissue‐Tek® O.C.T.™ Compound; Sakura Finetek Europe
BV, Alphen, NL), was performed to harvest vertical sec-
tions at entry point of injection and of surrounding in-
jection site with a slice thickness of 10 µm. Sections were
stained with H&E and qualitatively evaluated (LB) under
a light microscope with fourfold magnification.
Statistics
Mann–Whitney U tests compared papule diameter and
immediate drug distribution parameters from EVCM
images. Data were presented as median and interquartile
ranges. An α level of P< 0.05 was considered statistically
significant. Analyses were performed in SPSS version 25
(IBM Corporation; Armonk, NY).
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RESULTS
Papule as Clinical Endpoint
A distinct papule on the skin appeared after EPI
(n= 55). The pressure level was titrated up to 4 bar to
consistently produce a papule after each injection. The
pressure level did not appear to have a significant effect
on papule dimensions (n= 33; P= 0.288), with a diameter
of 6.0mm (6.0–7.0) at 4 bar and 7.0mm at 6 bar
(6.0–7.5mm; Fig. 1A and B).
Dermal Drug Distribution
EPI with 4 and 6 bar pressure levels resulted in
a comparable dispersion of contrast agent reaching
upper, mid, and deep dermis with an axial distribution
of 2319 µm (1500–2900 µm; 4 bar) and 2399 µm (2024–
2758 µm; 6 bar; P= 0.842; Fig. 2; Table 1). Lateral
dispersion for 4 and 6 bar pressure levels were also
similar resulting in a lateral distribution of 5944 µm
(5173–6861 µm; 4 bar) and 6187 µm (5351–6544 µm; 6 bar;
P= 0.905).
The most commonly observed distribution pattern re-
sembled a hemispherical shape for both 4 and 6 bar
pressure levels (Fig. 2A‐C). However, variations in shape
were observed between single injections resembling, for
example, triangular deep‐dermal or flat upper‐dermal
distribution patterns (Figs. 2D‐F and 3). Overall, epi-
thelium of hair follicles and epidermal entry point of in-
jection showed high uptake of AO. The subcutaneous layer
was reached sporadically.
Skin Architecture Disruption
Confocal microscopy images demonstrated disruption of
normal skin structure after EPI with multiple vacuoles
surrounding the dermal injection site and sub‐epidermal
clefting, independent of pressure levels (Fig. 3). The epi-
dermis was torn apart at the entry point while architec-
tural structure of the subcutaneous layer remained intact.
Tissue disruption after EPI was confirmed on histo-
logical sections displaying vacuoles, fragmented collagen,
and tissue gaps in the dermis, to a similar degree at 4 and
6 bar pressure levels (Fig. 4). Disruption was most pro-
nounced in sections closest to the point of entry. In con-
trast to confocal microscopy images, signs of epidermal
trauma were not visible but sporadic disruption of sub-
cutaneous tissue was seen.
DISCUSSION
We conducted an experimental ex vivo porcine study in
which immediate EPI‐assisted drug delivery was inves-
tigated using EVCM and histological sections. Our results
demonstrate that a papule on normal skin is a reprodu-
cible clinical endpoint for EPI and indicates dermal drug
delivery throughout all layers of the dermis, independent
of pressure level settings. In laser and light treatments,
clinical endpoints already have been shown to be helpful
for safe and effective treatments; for example, immediate
whitening of the skin after laser treatment using
Q‐switched lasers for tattoo removal [30]. In our study, we
found that a skin papule has been consistently produced
with a minimum pressure level of 4 bar. However, this
Fig. 1. Skin papule as clinical endpoint. A skin papule served as predefined, clinical endpoint
after electronic pneumatic injection (50 µl/injection) at 4 bar (A) and 6 bar (B). The pressure level
did not have a significant effect on papule dimensions (P= 0.288), with a diameter of 6.0 mm
(6.0–7.0) at 4 bar and 7.0mm at 6 bar (6.0–7.5mm). The nozzle of the electronic pneumatic
injection device is shown (C).
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pressure level may not be directly translated into a clin-
ical setting, as human dermis is generally thinner than
porcine skin. Also, the pressure level required to induce a
papule may vary when treating different anatomical lo-
cations or skin lesions with higher consistencies (e.g.,
hypertrophic scars or keloids).
In this study, we used EVCM as a high‐resolution
imaging technique. The EVCM had an acquisition time of
approximately 3–5minutes, while preparation of cry-
osections requires 20–45minutes per tissue sample [22].
Beside the benefit of minimal waiting time, tissue in-
tegrity remained intact and provided a realistic view on
skin architecture and immediate drug distribution.
Analyses of EVCM images showed that both 4 and 6 bar
pressure levels generated deep dermal drug delivery.
Spatial distribution of dermal drug delivery has also been
investigated using a similar EPI device at 3.1, 3.9, and
4.6 bar pressure levels and 80 µl injection volume by
Erlendsson et al. [31], however, with ink as a contrast
agent and assessment of drug distribution on histological
sections only. In the study by Erlendsson et al., lateral
dispersion was found to be pressure independent for in-
dividual injections, which is similar to our results.
Notably, the lateral dispersion increased when stacking
two consecutive injections at the same site, however,
stacking of injections was not investigated in our study.
For axial dispersion, a significant increase was observed
when the highest pressure level of 4.6 bar was used for
individual injections. This suggests that axial dispersion
could be pressure dependent at lower pressure levels,
while the dispersion is pressure independent between
Fig. 2. Electronic pneumatic injection induces deep dermal drug delivery. Fluorescence and
composite images were captured using an ex vivo confocal microscope. Images show comparable
fluorescent drug distribution of acridine orange in deep dermis following electronic pneumatic
injection at 4 and 6 bar pressure level (acridine orange solution is green on fluorescence images
and purple on composite images). The most commonly observed distribution pattern was
hemispherical (A, B, and C). Mild variations in shape have been observed for both pressure levels
(D, E, and F). (A–F) display separate representative biopsies.
TABLE 1. Spatial Distribution of Acridine Orange
Pressure
level
Number of
biopsies
Axial, median
in µm (IQR)
Lateral,
median in
µm (IQR)
4 bar 10 2319
(1500–2900)
5944
(5173–6861)
6 bar 9 2399
(2024–2758)
6187
(5351–6544)
Spatial distribution of acridine orange in porcine dermis ad-
ministered with electronic pneumatic injection, visualized by ex
vivo confocal microscopy, defined as axial and lateral dermal drug
distribution.
IQR, interquartile range.
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4 and 6 bar according to our findings. Seok et al. [13] has
found similar EPI‐induced spatial distribution for 6 bar
with an axial distribution of 2323 µm compared with
2399 µm found in this study. Although no difference in
spatial distribution was observed between 4 and 6 bar
pressure level, we did observe a variation in distribution
patterns, including hemispherical dispersion projecting
from injection site, a deep‐dermal distribution with a
triangular appearance, and a flat upper‐dermal dis-
tribution with a small penetration depth. This variation
could possibly be explained by a difference in tissue con-
sistencies within the skin sample and/or variation in
Fig. 3. Disrupted skin architecture by electronic pneumatic injection. Composite image showing
skin architecture (pink) disrupted by electronic pneumatic injection with acridine orange (purple)
at 6 bar pressure level (left) and an untreated biopsy (right) using ex vivo confocal microscopy.
Tissue disruption was similar for 4 and 6 bar pressure level. *, epidermal trauma at entry point of
injection; ■, clefting between stratum basale and dermis;▲, vacuoles in the dermis.
Fig. 4. Skin architecture disruption visualized on histology images. On frozen tissue sections,
skin architecture disruption induced by electronic pneumatic injection was observed as vacuoles,
fragmented collagen, and tissue gaps in the dermis. Three sections are shown of one
representative biopsy for both 4 and 6 bar. The tissue disruptions are more prominent in close
proximity to the point of entry. Untreated control with intact skin architecture is shown for
comparison.
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residue formation on top of the skin. Michinaka et al. [32]
showed that the dispersion area of spring‐driven jet in-
jector relates inversely to the size of injected particles but
proportionally to injection volume. Rohilla et al. [33]
showed a significant effect on penetration depth, which
could alter the distribution pattern, when comparing fluid
viscosity in vitro using a spring‐driven jet injector. The
different working mechanisms of spring‐driven jet in-
jectors and EPI, however, preclude direct comparison of
device parameters.
EPI‐induced dermal skin structure disruption was vi-
sualized by EVCM images and histological sections, al-
though with a slightly different presentation. The dis-
tinction could be explained by tissue alterations due to slow
freezing, biopsy storage at −80℃, and tissue processing,
which may have stretched the fragile tissue, exposing
fragmented collagen and tissue gaps on histological sec-
tions [17]. Skin structure disruption of the dermis plays an
important role in long‐term effects of treatments focusing
on skin remodeling. It activates the wound‐healing process
including the remodeling phase, which consists of collagen
augmentation, crosslinking, and skin contraction for at
least 6 months [12,15,34]. Previous studies have related
EPI‐induced neocollagenesis to a beneficial long‐term effect
of 4–6 months in rhytids [12,35], in contrast to the short‐
term effects seen after needle injection with, for example,
hyaluronic acid and saline [35].
EPI's ability to provide deep dermal drug delivery may
be particularly advantageous for dermatological con-
ditions in which treatment specifically targets the dermis.
In accordance, preliminary positive outcomes have been
reported for keloids, acne scars, wrinkle treatment,
palmar and axillar hyperhidrosis, local anesthetics, photo
dynamic therapy for non‐melanoma skin cancer, and nail
psoriasis [36–41]. However, none of these studies focused
on a clinical endpoint as in our study, which is important
for guiding the treating physician in clinical practice.
Limitations in visualization of EPI‐induced dermal
drug delivery in this study includes the use of ex vivo pig
skin to model in vivo human skin [42], uncertainty to
what degree drugs used in clinical practice will behave
similarly to AO, the lack of kinetic evaluation of cuta-
neous drug distribution, and the lacking assessment of a
minimum threshold for AO detection with EVCM. More-
over, cryosectioning was used to assess tissue morphology
with a moderate risk of artifacts, image assessment
lacked a blinded second evaluator, and in order to stand-
ardize interventions, we only applied a fixed volume of
50 µl compared at 4 and 6 bar.
For future research we suggest to further investigate
other factors that could impact the spatial dispersion of
EPI, including different injection volumes, variation in
residue formation on top of the skin, and stacking of in-
jections.
CONCLUSION
This is the first study that relates a reproducible clin-
ical endpoint to immediate EPI‐assisted drug delivery and
tissue disruption using reflectance and fluorescence con-
focal microscopy images and histological sections. An EPI‐
induced skin papule indicates dermal drug delivery
throughout all layers of the dermis, independent of pres-
sure level settings.
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